期刊文献+

糖皮质激素对其受体、热休克蛋白90和组蛋白去乙酰化酶6的影响及中药干预研究 被引量:2

The Change of GR,HSP90 and HDAC6 after the Use of Glucocorticoid and the Intervention of Traditional Chinese Medicine
下载PDF
导出
摘要 目的检测应用肾上腺糖皮质激素后激素受体(GR)、热休克蛋白90(HSP90)和组蛋白去乙酰化酶6(HDAC6)的变化及应用中药后对其干预情况。方法采用实时定量PCR方法检测正常对照组、地塞米松组及地塞米松加中药组的GR、HSP90和HDAC6的mRNA表达情况。结果与正常对照组相比,地塞米松组和地塞米松加中药组GR的表达水平均明显降低,差异有统计学意义。地塞米松组HSP90β mRNA表达水平与正常对照组相比明显降低,地塞米松加中药组HSP90β mRNA表达水平比地塞米松组升高,而比正常对照组低。地塞米松加中药组HDAC6 mRNA明显高于正常对照组和地塞米松组,差异有统计学意义。结论应用糖皮质激素后GR减少;应用糖皮质激素后HSP90β减少,右归丸对其略有改善;应用糖皮质激素后再应用右归丸HDAC6升高。 Objective To detect the change of GR,HSP90 and HDAC 6 after the use of adrenal cortex hormone and the intervention of traditional Chinese medicine(TCM).Methods The expression of GR,HSP90 and HDAC6 in control group,dexamethasone group and dexamethasone TCM group were detected by using realtime-PCR.Results Compared with the control group,the expression level of GR mRNA of the dexamethasone group and the dexamethasone TCM group decreased clearly,and the difference is very clear.Compared with the control group,the expression level of HSP90β mRNA of the dexamethasone group decreased clearly,compared with the dexamethasone group,the expression level of HSP90β mRNA of the dexamethasone TCM group increased clearly,but is lower than that of control group.The HDAC6 mRNA level of the dexamethasone TCM group is much higher than the control group and dexamethasone group.Conclusion The expression level of GR decreased after the use of glucocorticoid.The expression level of HSP90β decreased after the use of glucocorticoid,and YOUGUIWAN improved the expression.The expression level of HDAC6,increased after the use of glucocorticoid followed by the use of YOUGUIWAN.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2010年第8期607-609,共3页 Journal of China Medical University
基金 国家自然科学基金资助项目(30872277) 教育部创新团队支持计划项目(IRT0760) 辽宁省教育厅创新团队项目(2008T197)
关键词 糖皮质激素受体 热休克蛋白90 组蛋白去乙酰化酶6 glucocorticoid receptor heat shock protein 90 histone deacetylase 6
  • 相关文献

参考文献9

二级参考文献62

  • 1Ichinose M,Sugiura H,Yamagata S,et al.[J].Am J Respir Crit Care Med,2000,162(2 pt 1):701-706. 被引量:1
  • 2Ito K,Lim S,Caramori G,et al.[J].PNAS,2002,99 (13):8921-8926. 被引量:1
  • 3Calverley P,Pauwels R,Vestbo J,et al.[J].Lancet,2003,361 (9356):449-456. 被引量:1
  • 4Ito K,Barnes PJ,Adcock IM.[J].Mol Cell Biol,2000,20 (18):6891-6903. 被引量:1
  • 5Ito K,Watanabe S,Kharitonov S,et al.[J].Eur Respir J,2001,18 (Suppl):316. 被引量:1
  • 6Ito K,Ito M,Elliott WM,et al.[J].N Engl J Med,2005,352 (19):1967-1976. 被引量:1
  • 7Tomita K,Barnes PJ,Adcock IM.[J].Biochem Biophys Res Comm,2003,301 (2):572-577. 被引量:1
  • 8Rahman I.[J].J Biochem Mol Biol,2003,36 (1):95-109. 被引量:1
  • 9Global Initiative for Chronic Obstructive Lung Disease.Global Strategy for the Diagnosis,Management and Prevention of Chronic Obstructive Pulmonary Disease.NHLBI/WHO workshop report.Bethesda,National Heart,Lung and Blood Institute,April 2001; Update of the Management Sections,GOLD website(www.goldcopd.com).Date updated:July 2004. 被引量:1
  • 10Barnes PJ.[J].Am J Respir Crit Care Med,2000,161(2 Pt 1):342-344. 被引量:1

共引文献33

同被引文献53

引证文献2

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部